<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref019">
 <label>19</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>D’Ambrosio</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Pasulo</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Puoti</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Vinci</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Schiavini</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Lazzaroni</surname>
   <given-names>S</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C</article-title>. 
  <source>J Hepatol</source>. 
  <year>2019</year>
  <month>3</month>;
  <volume>70</volume>(
  <issue>3</issue>):
  <fpage>379</fpage>–
  <lpage>87</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.jhep.2018.11.011</pub-id>
  <?supplied-pmid 30472321?>
  <pub-id pub-id-type="pmid">30472321</pub-id>
 </mixed-citation>
</ref>
